Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.27 (
thermolysin
)
1,894
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Tumor cell invasion and metastasis is a multifactorial process, which at each step may require the action of proteolytic enzymes such as collagenases, cathepsins, plasmin, or plasminogen activators. An enzymatically inactive proenzyme form of the urokinase-type plasminogen activator (pro-uPA) is secreted by tumor cells which may be converted to an enzymatically active two-chain
uPA
-molecule (HMW-uPA) by plasmin-like enzymes. Action of proteases on pro-
uPA
may generate the enzymatically active or inactive high-molecular-weight form of
uPA
(HMW-uPA). Some proteases (plasmin, cathepsin B and L, kallikrein, trypsin or
thermolysin
) activate pro-
uPA
by cleaving the peptide bond Lys158 and IIe159. Other proteases (elastase, thrombin) cleave pro-
uPA
at different positions to yield enzymatically inactive HMW-
uPA
. HMW-
uPA
may be split into the enzymatically active LMW-
uPA
and the enzymatically inactive ATF (amino terminal fragment). ATF may be cleaved between peptide sequence 20 and 40 within the receptor binding domain of
uPA
(GFD). Such impaired ATF does not bind to
uPA
-receptors. Action of the bacterial endoproteinase Asp-N from Pseudomonas fragi mutant on pro-
uPA
or HMW-
uPA
, however, generates intact ATF which efficiently competes for binding of HMW-
uPA
or pro-
uPA
to receptors on tumor cells. High
uPA
-antigen content (pro-uPA, HMW-uPA, or LMW-uPA) in breast cancer tissue (not in plasma) indicates an elevated risk for the patient of recurrences and shorter overall survival. Thus pro-
uPA
/
uPA
-antigen content in breast cancer tissue serves as an independent prognostic parameter for the outcome of the disease. Cathepsin D is also an independent prognostic factor for recurrences and overall survival. High content of cathepsin D in breast cancer tumors is, however, not correlated with elevated levels of pro-
uPA
/
uPA
indicating that synthesis and release of cathepsin D and pro-
uPA
/
uPA
are independent events.
...
PMID:Biological and clinical relevance of the urokinase-type plasminogen activator (uPA) in breast cancer. 180 51
The major opportunistic pathogen Staphylococcus aureus utilizes the human fibrinolytic system for invasion and spread via plasmin(ogen) binding and non-proteolytic activation. Because S. aureus secretes several proteases recently proposed as virulence factors, we explored whether these enzymes could add to the activation of the host's fibrinolytic system. Exposure of human pro-urokinase [pro-
uPA
(where
uPA
is urokinase-type plasminogen activator)] to conditioned growth media from staphylococcal reference strains results in an EDTA-sensitive conversion of the single-chain zymogen into its two-chain active form, an activity not observed in an aureolysin-deficient strain. Using purified aureolysin, we verified the capacity of this
thermolysin
-like metalloprotease to activate pro-
uPA
, with a 2.6 x 10(3) M(-1) x s(-1) catalytic efficiency. Moreover, activation also occurs in the presence of human plasma, as well as in conditioned growth media from clinical isolates. Finally, we establish that aureolysin (i) converts plasminogen into angiostatin and mini-plasminogen, the latter retaining its capacity to be activated by
uPA
and to hydrolyse fibrin, (ii) degrades the plasminogen activator inhibitor-1, and (iii) abrogates the inhibitory activity of alpha(2)-antiplasmin. Altogether, we propose that, in parallel with the staphylokinase-dependent activation of plasminogen, aureolysin may contribute significantly to the activation of the fibrinolytic system by S. aureus, and thus may promote bacterial spread and invasion.
...
PMID:The human fibrinolytic system is a target for the staphylococcal metalloprotease aureolysin. 1797 26
Pathogenic bacteria, including Pseudomonas aeruginosa, interact with and engage the host plasminogen (Plg) activation system, which encompasses the urokinase (
uPA
)-type Plg activator, and is involved in extracellular proteolysis, including matrilysis and fibrinolysis. We hypothesized that secreted bacterial proteases might contribute to the activation of this major extracellular proteolytic system, thereby participating in bacterial dissemination. We report that LasB, a
thermolysin
-like metalloprotease secreted by Ps. aeruginosa, converts the human
uPA
zymogen into its active form (kcat=4.9 s-1, Km=8.9 microM). Accordingly, whereas the extracellular secretome from the LasB-expressing pseudomonal strain PAO1 efficiently activates pro-
uPA
, the secretome from the isogenic LasB-deficient strain PDO240 is markedly less potent in pro-
uPA
activation. Still, both secretomes induce some metalloprotease-independent activation of the human zymogen. The latter involves a serine protease, which we identified via both recombinant protein expression in Escherichia coli and purification from pseudomonal cultures as protease IV (PIV; kcat=0.73 s-1, Km=6.2 microM). In contrast, neither secretomes nor the pure proteases activate Plg. Along with this, LasB converts Plg into mini-Plg and angiostatin, whereas, as reported previously, it processes the
uPA
receptor, inactivates the plasminogen activator inhibitor 1, and activates pro-matrix metalloproteinase 2. PIV does not target these factors at all. To conclude, LasB and PIV, although belonging to different protease families and displaying quite different substrate specificities, both activate the urokinase-type precursor of the Plg activation cascade. Direct pro-
uPA
activation, as also reported for other bacterial proteases, might be a frequent phenomenon that contributes to bacterial virulence.
...
PMID:Activation of human pro-urokinase by unrelated proteases secreted by Pseudomonas aeruginosa. 2033 95